Skip to main content
See every side of every news story
Published • loading... • Updated

One of Europe’s Leading VCs Banks a €725M ‘Crossover’ Fund

Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.

12 Articles

Joplin GlobeJoplin Globe
+3 Reposted by 3 other sources
Center

Sofinnova Partners Closes €725M Crossover II Fund

PARIS--(BUSINESS WIRE)--Nov 16, 2026-

Read Full Article

L'article Sofinnova Partners raises 725 million euros for its Crossover II fund est apparu en premier sur Maddyness - Le média pour comprendre le économie demain.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources lean Left
60% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Business Wire broke the news in Crystal River, United States on Sunday, November 15, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal